drugset / Trial / NCT00381485

Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)

NCT00381485 ↗

Phase 3 Completed 834 enrolled Organon and Co Novartis · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, multicenter, double blind, parallel-group study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) compared with MF MDI 400 mcg BID for 12 weeks. Prior to the 12-week double-blind treatment period, subjects will receive open-label MF MDI 400 mcg BID for 2 to 3 weeks during the run-in period. Efficacy will be measured by the area under the curve from 0 to 12 hours \[AUC\](0-12 hr) of the change from Baseline to the Week 12 Endpoint in forced expiratory volume in one second (FEV1).

Timeline

Start
2006-07-01
Primary completion
2008-01-01
Completion
2008-01-01

Outcome

Met primary endpoint

paper MF/F 400/10 microg (4.19 L x hour) versus MF 400 microg (2.04 L x hour; p < 0.001). PMID 20687982 ↗

registry analysis (unspecified test); MF/F MDI 400/10 mcg BID vs MF MDI 400 mcg BID; p <0.001; ANCOVA NCT00381485 ↗

registry analysis (unspecified test); MF/F MDI 200/10 mcg BID vs MF MDI 400 mcg BID; p <0.001; ANCOVA NCT00381485 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 10 ug Inhaled
Subject Mometasone furoate Other / unclassified 200 ug Inhaled
Subject Mometasone furoate Other / unclassified 400 ug Inhaled

Indications